ENA713D
Drug
Novartis Pharma AG
Total Payments
$10,105
Transactions
2
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $10,105 | 2 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $10,089 | 1 | 99.8% |
| Travel and Lodging | $16.00 | 1 | 0.2% |
Top Doctors Receiving Payments for ENA713D
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Gary Small | Psychiatry | Los Angeles, CA | $10,105 | 2 |
Ad
Manufacturing Companies
- Novartis Pharma AG $10,105
Product Information
- Type Drug
- Total Payments $10,105
- Total Doctors 1
- Transactions 2
About ENA713D
ENA713D is a drug associated with $10,105 in payments to 1 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.
Payment data is available from 2018 to 2018. In 2018, $10,105 was paid across 2 transactions to 1 doctors.
The most common payment nature for ENA713D is "Consulting Fee" ($10,089, 99.8% of total).